A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multi-center Study to Evaluate the Efficacy and Safety of GB001 as Maintenance Therapy in Adult Subjects With Moderate to Severe Asthma
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multi-center Study to Evaluate the Efficacy and Safety of GB001 as Maintenance Therapy in Adult Subjects With Moderate to Severe Asthma
A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe asthma and an eosinophilic phenotype with respect to asthma worsening at the end of 24 weeks of treatment.
Inclusion Criteria
Exclusion Criteria
Other protocol-defined inclusion/exclusion criteria may apply.
Los Angeles, California 90048, United States
San Diego, California 92123, United States
San Jose, California 95117, United States
Oklahoma City, Oklahoma 73131, United States
Madison, Wisconsin 53792-9988, United States
Vienna, Austria
Montreal, Canada
Hradec Králové, Czechia
Olomouc, 779 00, Czechia
Santiago de Compostela, A Coruna 15706, Spain
Dnipro, 49006, Ukraine
Kyiv, 03680, Ukraine
Kyiv, Ukraine
Zaporizhia, 69035, Ukraine
Zaporizhia, 69104, Ukraine